drugset / Trial / NCT04508842
CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL)
Phase 1
Terminated
2 enrolled
Hebei Yanda Ludaopei Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single center, single arm, open-lable phase I study to determine the safety and efficacy of CD19/CD22-Dual-STAR-T cells in patients with refractory and relapsed B cell acute leukemia .
Timeline
- Start
- 2020-10-10
- Primary completion
- 2022-05-01
- Completion
- 2022-05-01
Outcome
Outcome not reported
Stopped: “Adjustment plan”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19/CD22-Dual-STAR-T | Unknown | 600000 cells/kg | Intravenous |
| Subject | CD19/CD22-Dual-STAR-T | Unknown | 1e+06 cells/kg | Intravenous |
| Subject | CD19/CD22-Dual-STAR-T | Unknown | 2e+06 cells/kg | Intravenous |
| Subject | CD19/CD22-Dual-STAR-T | Unknown | 3e+06 cells/kg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 500 mg/m2 | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |